ALX Oncology Exchanges 13,353,384 Common Shares for Pre-Funded Warrants

• ALX Oncology agreed October 14, 2026, to exchange 13,353,384 common shares for pre-funded warrants covering the same number of shares.
• Blackstone-affiliated funds account for 12,885,891 shares; RA Capital Healthcare Fund, 213,667; venBio Global Strategic Fund, 253,826.
• The unregistered issuance relies on a Section 3(a)(9) exemption, with settlement expected on or about October 15, 2026.
• Warrants carry a $0.001-per-share exercise price, exercisable from issuance until fully exercised through cash payment or cashless exercise.
• Exercise is subject to 4.99% or 9.99% ownership caps; holders may raise caps to 19.99%, effective 61 days following notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-422992), on October 15, 2026, and is solely responsible for the information contained therein.